Analyst Price Target is $4.16
▲ +340.26% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for CytoMed Therapeutics in the last 3 months. The average price target is $4.16, with a high forecast of $4.16 and a low forecast of $4.16. The average price target represents a 340.26% upside from the last price of $0.94.
Current Consensus is
Hold
The current consensus among 2 polled investment analysts is to hold stock in CytoMed Therapeutics. This rating changed within the last month from a Sell consensus rating.
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.
Read More
